Monopar Therapeutics (NASDAQ:MNPR) Given New $125.00 Price Target at HC Wainwright

Monopar Therapeutics (NASDAQ:MNPR) had its target price lifted by HC Wainwright from $105.00 to $125.00 in a research report report published on Wednesday,Benzinga reports. The firm currently has a buy rating on the stock.

Several other analysts have also recently issued reports on the company. Wall Street Zen cut Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, July 12th. UBS Group set a $105.00 price target on shares of Monopar Therapeutics in a research note on Monday, June 29th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, July 15th. Zacks Research upgraded shares of Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. Finally, BTIG Research upped their target price on shares of Monopar Therapeutics from $104.00 to $117.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Three research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $110.42.

Monopar Therapeutics Stock Down 1.0%

Shares of MNPR stock opened at $112.48 on Wednesday. The company’s fifty day simple moving average is $78.59 and its two-hundred day simple moving average is $66.08. Monopar Therapeutics has a 52 week low of $29.18 and a 52 week high of $116.64. The stock has a market cap of $753.62 million, a P/E ratio of -59.20 and a beta of 1.46.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.41. On average, analysts anticipate that Monopar Therapeutics will post -2.82 EPS for the current fiscal year.

Institutional Trading of Monopar Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. purchased a new position in shares of Monopar Therapeutics during the third quarter valued at approximately $28,000. BNP Paribas Financial Markets lifted its stake in shares of Monopar Therapeutics by 100.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after acquiring an additional 349 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in Monopar Therapeutics during the 4th quarter valued at $65,000. Caitong International Asset Management Co. Ltd bought a new position in Monopar Therapeutics in the 4th quarter valued at $86,000. Finally, JPMorgan Chase & Co. increased its stake in Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after purchasing an additional 1,821 shares during the period. 1.83% of the stock is owned by hedge funds and other institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.